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Severity of obesity and management of hypertension,
hypercholesterolaemia and smoking in primary care:
population-based cohort study
HP Booth, AT Prevost and MC Gulliford
Obesity and obesity-associated cardiovascular risk are increasing worldwide. This study aimed to determine how different levels of
obesity are associated with the management of smoking, hypertension and hypercholesterolaemia in primary care. We conducted a
cohort study of adults aged 30–100 years in England, sampled from the primary care electronic health records in the Clinical Practice
Research Datalink. Prevalence, treatment and control were estimated for each risk factor by body mass index (BMI) category.
Adjusted odds ratios (AOR) were estimated, allowing for age, gender, comorbidity and socioeconomic status, with normal weight as
reference category. Data were analysed for 247 653 patients including 153 308 (62%) with BMI recorded, of whom 46 149 (30%) were
obese. Participants were classiﬁed into simple (29 257), severe (11 059) and morbid obesity (5833) categories. Smoking declined with
the increasing BMI category, but smoking cessation treatment increased. Age-standardised hypertension prevalence was twice as
high in morbid obesity (men 78.6%; women 66.0%) compared with normal weight (men 37.3%; women 29.4%). Hypertension
treatment was more frequent (AOR 1.75, 1.59–1.92) but hypertension control less frequent (AOR 0.63, 0.59–0.69) in morbid obesity,
with similar ﬁndings for severe obesity. Hypercholesterolaemia was more frequent in morbid obesity (men 48.2%; women 36.3%)
than normal weight (men 25.0%; women 20.0%). Lipid lowering therapy was more frequent in morbid obesity (AOR 1.83, 1.61–2.07)
as was cholesterol control (AOR 1.19, 1.06–1.34). Increasing obesity category is associated with elevated risks from hypertension and
hypercholesterolaemia. Inadequate hypertension control in obesity emerges as an important target for future interventions.
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INTRODUCTION
Obesity is a growing global health concern, with a rapid increase
being observed in morbid obesity. Excess body weight is
associated with an increased cardiovascular risk and earlier onset
of cardiovascular morbidity.1 It is well established that obesity is
associated with activation of both the sympathetic nervous
system and the renin–angiotensin system contributing to the
emergence of hypertension.2 Epidemiological studies have
demonstrated the importance of the level and duration of obesity
as risk factors for cardiovascular disease.3 Improved preventive
medical care to detect, treat and control of risk factors in
overweight and obese patients is therefore of particular
importance.4 Smoking, high blood pressure (BP) and elevated
serum cholesterol levels represent major cardiovascular risk
factors5 that are routinely managed in primary care settings.
Deﬁcits in risk factor detection, treatment and control are well
recognised. The ‘rule of halves’ has been applied to hypertension
management, which suggests that half of hypertension may be
detected, with half of these treated and half controlled.6 In the UK
general population, hypertension detection, treatment and con-
trol have improved over time with closer to ‘two-thirds’ now being
detected, treated or controlled.6 Some studies suggest that
hypertension may be less well controlled in obese patients,7–9
but few studies have been sufﬁciently large to analyse patients
with severe and morbid obesity as separate groups. Management
of hypercholesterolaemia and smoking at different levels of
obesity have been less studied.7 In the UK, a population-based
system of primary care, in which patients remain registered with
the same general practice for many years, enables the health care
system to potentially address these important concerns. This study
aimed to compare the diagnosis and treatment of smoking,
hypertension and hypercholesterolaemia, and control of hyper-
tension and hypercholesterolaemia, according to body mass index
(BMI) category by using the electronic health records of a large
population in primary care.
METHODS
Study design and participants
CPRD is a prospectively collected database of primary care electronic
health records, from ~680 UK general practices with 5.5 million currently
registered patients.10 For the present study, data were sampled from CPRD
general practices in England that participate in the data linkage scheme. A
random sample of patients registered in CPRD, aged 30 years or older, was
drawn. This provided an initial cohort of 300 006 patients. These analyses
evaluated records during 2011 and we included all 247 653 participants,
with 122 903 men and 124 750 women, who contributed person-time in
2011. Ethical approval for the study was given by the CPRD Independent
Scientiﬁc Advisory Committee (ISAC 09_085 & 14_056).
Outcomes and covariates
BMI records were evaluated and BMI was also calculated from weight and
height records where appropriate. Measurements from up to 3 years
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previously were analysed.11 Patients were classiﬁed by BMI using the
categories: underweight, BMIo18.5 kgm−2; normal weight, 18.5–24.9 -
kgm− 2; overweight, 25.0–29.9 kgm− 2; obese, 30.0–34.9 kgm−2; severe
obesity, 35.0–39.9 kgm−2; and morbid obesity, ⩾ 40 kgm−2. Patients with
missing BMI status were included in the analyses as a separate category.
Smoking status was ascertained by using clinical records of smoking
habits (including cigarettes, pipe, cigar and unspeciﬁed smoking) together
with records of advice, referrals to stop smoking services and drug
prescriptions for nicotine replacement therapy, as reported in detail
previously.12 Participants not recorded as smokers or ex-smokers were
classed as non-smokers.12 Records of smoking cessation advice, referrals or
prescriptions for nicotine replacement therapy were used to indicate
treatment for smoking cessation. ‘Control’ of smoking was not evaluated as
clinical records of quitting and relapse may be incomplete.
Hypertension was deﬁned as a BP reading of ⩾ 140/90mmHg or
treatment with antihypertensive drugs.13 Antihypertensive drugs were
categorised by using the ‘ABCD’ classiﬁcation, including: A, angiotensin-
converting enzyme inhibitors and angiotensin receptor blocking drugs; B,
beta blockers; C, calcium channel blockers; and D, thiazide diuretics.13
Hypercholesterolaemia was deﬁned as a total cholesterol measurement
45mmol l− 1 or treatment with lipid-lowering drugs. Treatment of each
condition was assessed based on the prescription of antihypertensive
drugs or lipid-lowering drugs. Successful control was deﬁned as a BP
o140/90mmHg, or total cholesterol ⩽ 5mmol l− 1. Socioeconomic
deprivation was assessed by using the Index of Multiple Deprivation rank
based on patient postal code and divided into quintiles for England.14
Data analysis
Age-standardised prevalences for smoking, hypertension and hypercho-
lesterolaemia were calculated for using the European Standard Population
for reference.15 Multivariable logistic regression models were used to
compare the proportion receiving treatment across BMI categories. In
order to evaluate whether treatment of risk factors differed depending on
the need for primary or secondary prevention, sensitivity analyses were
performed by excluding patients with comorbid coronary heart disease
(CHD), stroke or type 2 diabetes from analyses. Models were adjusted for
age and gender, prevalent CHD, stroke, diabetes and deprivation quintile.
RESULTS
The initial cohort comprised 300 006 patients. For the present
analyses, we included all 247 653 participants, with 122 903 men
and 124 750 women, who contributed person-time in 2011. The
mean age was 56.0 (s.d. 14.3) for men and 57.7 (s.d. 15.4) for
women. There were 153 308 (62%) with BMI values recorded in
the preceding three years, including 29 257 (19%) with simple
obesity, 11 059 (7.2%) having severe obesity and 5833 (3.8%) with
morbid obesity. Among patients with known smoking status,
25.5% of men and 20.8% of women were current smokers.
Age-standardised prevalences for smoking, hypertension and
hypercholesterolaemia by gender and BMI category are presented
in Table 1. Current smoking was highest in underweight patients,
at 56.4% (95% conﬁdence interval (CI) 51.8–61.1) in men and
37.2% (34.5–39.8) in women. Smoking prevalence declined with
increasing BMI category, reaching 21.6% (19.6–23.6) in morbidly
obese men and 19.7% (18.3–21.0) in women. The prevalence of
hypertension and hypercholesterolaemia rose with increasing BMI
category. Hypertension was found to affect 78.6% (76.6–80.7) of
morbidly obese men and 66.0% (64.5–67.4) of morbidly obese
women, while hypercholesterolaemia was prevalent in 48.2%
(45.9–50.4) of morbidly obese men and 36.3% (34.9–37.7) of
women. The proportion with each risk factor was generally higher
in men than women in the same BMI category.
Figure 1 presents the proportion of patients with hypertension
receiving antihypertensive medication by BMI category. The
proportions receiving one, two, three or four classes of
antihypertensive medications are also shown. As BMI category
increased a higher proportion of hypertensive patients received
antihypertensive drug treatment. The proportion of patients
prescribed one class of drug decreased slightly in higher BMI
categories, from 47% of normal weight men to 37% of morbidly
obese men. However, there was only marginal increase in the
proportion receiving three or four classes of antihypertensive
drugs at higher levels of obesity. In women, the values were 49
and 48%, respectively.
Figure 2 presents the proportion of patients with treated
hypertension whose BP was controlled. As BMI category increased,
the proportion with controlled hypertension did not increase in
proportion to those treated, and tended to decrease in morbid
obesity (Table 3). However, for hypercholesterolaemia (Figure 3)
both the proportion treated and controlled increased with an
increasing BMI category (Tables 2 and 3).
Table 2 presents adjusted odds ratios (AOR) for the association
of BMI category with risk factor treatment. The odds of receiving
treatment for each of the three risk factors increased with
increasing BMI category. The effect of increasing BMI category was
greatest for treatment of hypercholesterolaemia, where obesity
Table 1. Age standardised prevalence (%) of smoking, hypertension and hypercholesterolaemia in men and women in 2011
BMI category N Smoking Hypertension Hypercholesterolaemia
Number of
smokers
ASR (95% CI) Number with BP
records
ASR (95% CI) Number with cholesterol
records
ASR (95% CI)
Men
Underweight 608 298 56.4 (51.8–61.1) 271 30.7 (26.8–34.5) 164 18.2 (14.9–21.4)
Normal weight 17 697 5045 33.2 (32.4–34.0) 8848 37.3 (36.5–38.0) 6300 25.0 (24.4–25.6)
Overweight 30 130 6425 24.4 (23.8–25.0) 18 278 49.5 (48.9–50.1) 13 385 33.6 (33.0–34.1)
Obese 14 683 3029 23.5 (22.6–24.3) 10 357 61.1 (60.2–62.0) 7379 39.9 (39.1–40.7)
Severely obese 4486 884 21.5 (20.1–22.9) 3470 71.0 (69.5–72.6) 2343 44.4 (42.9–46.0)
Morbidly obese 1927 402 21.6 (19.6–23.6) 1576 78.6 (76.6–80.7) 1025 48.2 (45.9–50.4)
Missing BMI 53 372 13 540 24.9 (24.5–25.3) 19 761 38.1 (37.7–38.5) 8544 17.0 (16.7–17.3)
Women
Underweight 1935 587 37.2 (34.5–39.8) 877 26.6 (24.6–28.5) 542 15.8 (14.1–17.5)
Normal weight 30 012 6677 23.5 (23.0–24.0) 11 559 29.4 (28.9–29.9) 7858 20.0 (19.6–20.4)
Overweight 26 777 5344 21.9 (21.3–22.5) 13 801 38.9 (38.4–39.5) 9424 25.9 (25.5–26.4)
Obese 14 574 2868 21.9 (21.2–22.7) 8706 49.2 (48.4–50.0) 5801 29.9 (29.2–30.6)
Severely obese 6573 1206 19.7 (18.6–20.7) 4286 57.3 (56.1–58.5) 2645 33.3 (32.3–34.4)
Morbidly obese 3906 745 19.7 (18.3–21.0) 2741 66.0 (64.5–67.4) 1566 36.3 (34.9–37.7)
Missing BMI 40 973 8186 21.1 (20.7–21.5) 16 228 33.0 (32.6–33.4) 7817 15.3 (15.0–15.7)
Abbreviations: ASR, age-standardised prevalence %; BMI, body mass index; CI, conﬁdence interval.
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was associated with odds of 1.59 (1.48–1.72, Po0.001) compared
with normal weight, and morbid obesity with an AOR of 1.83
(1.61–2.07, Po0.001). The absolute difference in proportion
treated was 10% (Table 2). For treatment of hypertension, the
AOR for morbid obesity was 1.75 (1.59–1.92, Po0.001) compared
with normal weight, with an absolute difference of 4%. For
smoking cessation therapy the AOR was 1.32 (1.11–1.58, P= 0.002),
with an absolute difference of 6%. Patients with missing BMI
status were less likely to be treated. Greater socioeconomic
deprivation was associated with a greater likelihood of receiving
treatment for hypertension (AOR 1.16, 95% CI 1.07–1.26, P= 0.001
most deprived vs least deprived quintile) and hypercholester-
olaemia (AOR 1.28, 95% CI 1.08–1.53, P= 0.005), but not for
smoking. Presence of co-morbidities was associated with greater
odds of treatment for each of the risk factors. To evaluate whether
obesity was associated with risk factor management in the
absence of cardiovascular comorbidity, we additionally excluded
data for patients with established CHD, stroke and type 2 diabetes
and observed similar associations.
Increasing BMI category was associated with lower hyperten-
sion control (Table 3). Morbidly obese patients with treated
hypertension had an AOR of 0.63 (0.57–0.69, Po0.001) compared
with normal weight patients and 7% fewer had their BP controlled.
The odds of controlled hypercholesterolaemia were greater in
morbidly obese patients compared with normal weight (AOR 1.19,
1.06–1.34, P= 0.005), with 7% more having the cholesterol values
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Figure 1. Use of antihypertensive drugs by BMI category. Proportion of hypertensive patients receiving different classes of
antihypertensive drugs.
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Figure 2. Treatment and control of hypertension by BMI category in 2011. Bars represent the proportion of hypertensive patients who
received treatment and those with a blood pressure measurement of o140/90 mmHg.
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controlled (Table 3). Control of hypertension and hypercholester-
olaemia was lower in those with missing BMI (AOR 0.65, 0.60–0.72,
Po0.001). A diagnosis of CHD, stroke and diabetes was associated
with greater odds of controlled hypertension and hypercholester-
olaemia, whilst socioeconomic deprivation was associated with
worse cholesterol, but not hypertension, control. Additional
analyses were performed, excluding patients with existing
diabetes CHD or stroke. These analyses showed that the
associations of hypertension control with BMI category were
similar in a primary prevention cohort but cholesterol control was
no longer associated with BMI category.
DISCUSSION
Summary of key ﬁndings
Obesity is associated with more frequent hypertension and
hypercholesteroalemia; higher rates of treatment for smoking,
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Figure 3. Treatment and control of hypercholesterolaemia by BMI category in 2011. Bars represent the proportion of patients with
hypercholesterolaemia who received the treatment and those with a total cholesterol measurement of ⩽ 5mmol l− 1.
Table 2. Multivariable logistic regression models for the treatment of smoking, hypertension and hypercholesterolaemia
N Treated (%) OR (95% CI) P-value
Smokinga
Underweight 885 95 (11) 0.74 (0.58, 0.95) 0.017
Normal weight 11 722 1648 (14) 1.00 —
Overweight 11 769 1830 (16) 1.08 (0.99, 1.18) 0.070
Obese 5897 993 (17) 1.16 (1.05, 1.29) 0.005
Severe obesity 2090 374 (18) 1.20 (1.04, 1.39) 0.016
Morbid obesity 1147 227 (20) 1.32 (1.11, 1.58) 0.002
Missing BMI 21 726 1571 (7) 0.51 (0.35, 0.93) o0.001
Hypertensiona,b
Underweight 1148 781 (68) 0.72 (0.62, 0.84) o0.001
Normal weight 20 394 13 787 (68) 1.00 —
Overweight 32 087 22 343 (70) 1.21 (1.16, 1.27) o0.001
Obese 19 064 13 744 (72) 1.50 (1.41, 1.58) o0.001
Severe obesity 7757 5707 (74) 1.75 (1.62, 1.88) o0.001
Morbid obesity 4319 3107 (72) 1.75 (1.59, 1.92) o0.001
Missing BMI 36 000 13 322 (37) 0.45 (0.41, 0.50) o0.001
Hypercholesterolaemiaa,b
Underweight 706 424 (60) 0.70 (0.58, 0.84) o0.001
Normal weight 14 158 9291 (66) 1.00 —
Overweight 22 809 16 574 (73) 1.35 (1.28, 1.43) o0.001
Obese 13 180 9957 (76) 1.59 (1.48, 1.72) o0.001
Severe obesity 4998 3852 (77) 1.83 (1.66, 2.02) o0.001
Morbid obesity 2591 1981 (76) 1.83 (1.61, 2.07) o0.001
Missing BMI 16 361 7426 (45) 0.70 (0.64, 0.78) o0.001
Abbreviations: BMI, body mass index; CI, conﬁdence interval; N, represents the number of patients with the risk factor; OR, odds ratio. aAdjusted for age,
gender, CHD, stroke, type 2 diabetes and socioeconomic status. bAdjusted for smoking status.
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hypertension and hypercholesterolaemia, but worse control of
hypertension. Separate estimates were presented for severe and
morbid obesity, showing that associations were graded according
to level of obesity. Control of hypertension was negatively
associated with BMI category, with morbidly obese patients less
likely to have controlled BP than those who were of normal
weight. Evaluation of the number of classes of antihypertensive
drugs prescribed showed that maximal antihypertensive therapy
was not utilised in a high proportion of patients. Further research
is needed to evaluate the use of different classes of drugs, and
different agents within classes, in order to identify optimal
hypertensive therapy for obese patients. Conversely, obesity was
associated with better control of total cholesterol. The absolute
magnitude of effects was modest but these small differences may
be of public health importance when a frequent condition is
managed in a large population.
Comparison with the literature
Obesity is known to be associated with greater cardiovascular
risk16 and a higher incidence of cardiovascular events.17 Hyper-
tension is associated with increased morbidity and mortality from
major cardiovascular diseases.18 The incidence17 and prevalence19
of hypertension are greater as BMI category increases. In the
Framingham cohort,20 obese individuals were more likely to
receive treatment for hypertension but there were no differences
in hypertension control. Less consistent associations have been
reported for treatment and control of hypercholesterolaemia. In
the Framingham study, hypercholesterolaemia, based on a cut-
point of 6.2 mmol l− 1, was not as strongly associated with obesity
as was hypertension,17 but rates of lipid-lowering therapy were
higher in the obese participants.20 However, several factors
potentially confound this relationship. Access and adherence to
lipid-lowering therapy may sometimes depend on the socio-
economic deprivation category.21
Strengths and limitations
The study had the strength of a very-large sample, drawn from a
nationally representative population of eligible participants. The
size of the sample enabled us to obtain precise estimates for
participants with severe and morbid obesity. However, we
acknowledge that analysis of clinical records for key measures
suffered from several limitations. Nearly 40% of participants did
not have recent BMI values recorded, consistent with the
infrequent monitoring of BMI in primary care.11 The distribution
of BMI category was generally similar to those observed in
national survey data22 but confounding by indication may arise if
BMI is more likely to be measured in patients who are ill or have
elevated risk factor values. Obese patients may be more likely to
have their BP and lipid levels documented compared with their
normal weight peers.23 Recording of measurements may be
associated with treatment. Errors in BP measurement may be
greater in more obese people, if a correctly ﬁtting BP cuff is not
used. The use of different drug classes may vary by obesity
category requiring further in-depth analysis. We reported on total
cholesterol values because lipoprotein fractions are less frequently
recorded into electronic health records. However, use of LDL:HDL
ratios might lead to different interpretations if HDL levels are
lower in obesity. We used a cut-point of 5 mmol l− 1 to deﬁne
hypercholesterolaemia and control, but lower treatment targets
are sometimes recommended. We were not able to analyse data
for some relevant confounders including physical activity, alcohol
consumption, educational level, ethnicity, family history or
duration of hypertension. We conducted sensitivity analyses to
evaluate the relevance of cardiovascular comorbidity for the
measures evaluated, but we acknowledge that there may be other
relevant co-morbidities, such as type 1 diabetes, which might be
present and lower frequency.
Implications for future research and practice
The results of this large population-based study reveal that
treatment and control of cardiovascular risk remain sub-optimal in
both obese and non-obese patients. However, the status of three
major modiﬁable risk factors for cardiovascular disease differs
according to weight status. Smoking is generally less frequent as
BMI increases but obese smokers are more likely to receive
smoking cessation therapy. Obese individuals more frequently
have hypercholesterolaemia, are more likely to receive treatment,
and tend to be slightly better controlled. However, while
hypertension is more frequent in obesity, and there is evidence
of a greater intensity of antihypertensive treatment as BMI
category increases, rates of hypertension control remain less
satisfactory. These associations were broadly consistent in men
and women but further research is required to explore possible
gender differences in the impact of obesity. The results identify
the increase in obesity as a major obstacle to improved
hypertension management, perhaps now threatening the con-
tinued decline in cardiovascular disease. While weight reduction
may be associated with improved BP and reduced cardiovascular
risk16 non-surgical weight-loss interventions presently have
generally limited long-term effects.24,25 Although the pathophy-
siological mechanisms of hypertension in obesity have been well
studied,2 the reasons why hypertension is more difﬁcult to control
in obese subjects deserve more research. Improved intervention
strategies, and optimal therapeutic interventions, for hypertension
in obesity may then be developed.
Table 3. Multivariable logistic regression models for the control of hypertension and hypercholesterolaemia in treated patients
Hypertension Hypercholesterolaemia
N Controlled (%) OR (95% CI)a,b P-value N Controlled (%) OR (95% CI)a P-value
BMI category
Underweight 781 501 (64) 0.84 (0.71–0.98) 0.031 424 202 (48) 0.63 (0.51–0.78) o0.001
Normal weight 13 787 9505 (69) 1.00 — 9291 5637 (61) 1.00 —
Overweight 22 343 15 341 (69) 0.93 (0.88–0.98) 0.004 16 574 10 645 (64) 1.10 (1.04–1.16) o0.001
Obese 13 744 9251 (67) 0.84 (0.79–0.89) o0.001 9957 6487 (65) 1.09 (1.03–1.16) 0.004
Severe obesity 5707 3759 (66) 0.78 (0.73–0.84) o0.001 3852 2520 (65) 1.08 (1.00 1.18) 0.059
Morbid obesity 3107 1912 (62) 0.63 (0.59 0.69) o0.001 1981 1343 (68) 1.19 (1.06 1.34) 0.005
Missing BMI 13 322 6746 (51) 0.54 (0.51 0.58) o0.001 7426 3073 (41) 0.65 (0.60 0.72) o0.001
Abbreviations: BMI, body mass index; CI, conﬁdence interval; N, number receiving treatment; OR, odds ratio. aControlling for age, gender, co-morbidities,
smoking status and socioeconomic status. bAlso controlling for number of antihypertensive drug classes.
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What is known about topic
● Obesity is increasing worldwide with especially rapid increases in
severe and morbid obesity.
● Preventive medical interventions to reduce obesity-associated
cardiovascular risk are important but few previous studies have
distinguished different levels of obesity severity.
What this study adds
● We analysed primary care electronic health record data for 153 308
participants including 46 149 who were obese, including 11 059
with severe obesity and 5833 with morbid obesity.
● We found that treatment of smoking and hypercholesterolaemia
increased with increasing body mass index category.
● Age-standardised hypertension prevalence was twice as high in
morbid obesity compared with normal weight. Although treatment
rates increased with BMI category, control of hypertension was less
likely to be achieved.
● Improved management of obesity and obesity-associated hyperten-
sion should be important objectives for preventive medical care.
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